

*Research Article***The effect of diacerein versus sulfasalazine on acetic acid-induced ulcerative colitis in rats****Walaa Y. Abdelzaher***, **Seham A. Abdel-Gaber*** and **Nisreen D.M. Toni****

* Department of Pharmacology, Faculty of Medicine, Minia University, Egypt.

** Department of Pathology, Faculty of Medicine, Minia University, Egypt.

Abstract

Ulcerative colitis is a serious premalignant condition has a confusing multifactorial pathogenesis. Researchers have attention for exploration of new therapeutic or prophylactic drugs targeting its pathophysiology. The current study was aimed to study the possible role of diacerein (50mg/kg/day) in ulcerative colitis rat model, induced by acetic acid. Twenty four male Wistar albino rats were classified into 4 groups: control group, acetic acid (AA)-ulcerated group, AA-ulcerated + diacerein (50 mg/kg/day) and AA-ulcerated + sulfasalazine (100 mg/kg/day) groups. Colonic malondialdehyde (MDA) and superoxide dismutase (SOD) were determined. Also, caspase-3 gene expression was measured as an indicator of apoptosis. Histopathological and COX2 immunohistochemical studies of the colonic tissue were also done. In addition, serum levels of interleukin (IL)-1 β and tumour necrosis factor (TNF)- α were measured. In AA-ulcerated group, there was significant elevation in tissue MDA levels with upregulation of caspase 3 gene expression. Meanwhile, AA caused decreases in the SOD activities. Also, AA induced elevation in the serum IL-1 β and TNF- α levels. Pretreatment with diacerein 50 mg/kg/day improved changes in these parameters. In conclusion, diacerein has beneficial effects against AA-induced damage of the colon, possibly by exerting anti-inflammatory, antioxidant and anti-apoptotic effects.

Key words: diacerein, ulcerative colitis, acetic acid, anti-apoptotic.**Introduction**

Inflammatory bowel disease (IBD) is a life threatening and debilitating disease affecting the colon including ulcerative colitis (UC) which is a premalignant disease, including oxidative and inflammatory factors in its pathogenesis (Karakoyun et al., 2011). Production of proinflammatory cytokines such as tumour necrosis factor alpha (TNF- α) is a corner stone inflammatory mediator in UC. The pathogenesis of IBD also involves activated T-cells, which release various cytokines responsible for production of free radicals and destructive enzymes, with injurious effect on the gastrointestinal tract (Wan et al., 2014). This occurs through apoptosis and can be progressed to colon cancer (Salari-Sharif and Abdollahi 2010). The sites of inflammation in UC have defective apoptotic functions (Sturm et al., 2008). Caspase-3, a key enzyme in apoptosis, is activated in apoptotic cells through both extrinsic and intrinsic pathways which lead

to colonic destruction with disturbed functions (Qiu et al., 2011).

Almost all drugs used in treatment of UC, aim at reducing symptoms or maintaining remission. Such as corticosteroids, immunosuppressants, aminosalicylates and biologic medications, but they can have side effects as hepatitis, nephritis, fluid retention, immunosuppression and others (Head and Jurenka 2003). Ongoing researches aim at exploring new remedies which may be of further benefit in ameliorating the disease or have additive or synergistic effects to the already used therapies for better disease prognosis with less side effects.

The interleukin-1 receptor antagonist is a member of the interleukin 1 cytokine family. IL1RA is secreted by various types of cells including immune cells, epithelial cells, and adipocytes, and is a natural inhibitor of the pro-inflammatory effect of

IL1 β . This protein inhibits the activities of interleukin 1, alpha (IL1 α) and interleukin 1, beta (IL1 β), and modulates a variety of interleukin 1 related immune and inflammatory responses (Perrier et al., 2006).

Diacerein is an antiinflammatory drug that is well established in treatment of osteoarthritis. It acts mainly via inhibition of interleukin-1 β (IL-1 β) synthesis (Domagala et al., 2004). It may act at the pre cell membrane level and the post cell membrane level but does not affect gene levels of IL-1 β . Diacerein downregulates the activity of IL-1 β by significantly decrease the number of IL-1 receptors (IL-1r) on the cell surface and by significantly increase the synthesis of IL1RA (Domagala et al., 2004).

Rhein, the active metabolite of diacerein, inhibits the production of IL-1 β *in vitro* and *in vivo*. Rhein also decreases the number of urokinase receptors to near normal levels and reduced fibrinolytic activity. Leukocyte migration, lysosomal enzyme release, super oxide production and chemotaxis, are also inhibited by rhein in dose dependent manner (Verbruggen, 2006).

The aim of this study was to extend the work of other researchers on the interleukin-1 receptor antagonist role in colitis and investigate the potential effects and mechanisms of action of diacerein in a rat model of AA-induced UC.

Materials and Methods

Drugs, chemicals and kits

Sulfasalazine (Pfizer, Australia) and diacerein (Eva pharma, Egypt) were used. Acetic acid glacial (CID pharmaceutical Co, Egypt) 4% (volume/volume), interleukin (IL)-1 β and tumor necrosis factor (TNF)- α enzyme-linked immunosorbent assay (ELISA) kits (Nanjing jiancheng Bioengineering, China) were used for analyses. Superoxide dismutase (SOD) colorimetric kits (Biodiagnostic, Egypt). Cyclo-oxygenase-2 (COX2) (Lab Vision Laboratories, Fermont, USA).

Animals

A total of 24 adult healthy male Wistar-albino rats weighing 180 to 220 g were used in this study. Rats were purchased

from the National Research Center, Cairo, Egypt. Rats were harbored on a 12-h light/dark cycle (lights on from 08:00 am) at a constant temperature (24 \pm 1 $^{\circ}$ C) and humidity with normal rat chow and water was available *ad libitum*. The study followed the guidelines for animal welfare and was approved by the Institutional Reviewer Board of Faculty of Medicine, Minia University.

Experimental design

Four groups of rats were studied (six rats in each). Group I: Normal control group that received only distilled water; Group II: AA-ulcerated, non-treated group, animals that received AA for UC induction (Mascolo et al., 1995); Group III: diacerein (50 mg/kg/day; PO)-treated group (Malaguti et al., 2008) + AA; Group IV: sulfasalazine (100 mg/kg/day; PO)-treated group (Thippeswamy et al., 2011) + AA.

Induction of colitis

After fasting overnight, rats were anesthetized with ether then intrarectally infused with 2 ml AA (4%) using a lubricated paediatric catheter inserted 8 cm proximal to the anus. Rats were kept in a horizontal position for 30 s to avoid AA leakage. The normal control group received an equal volume of 0.9% saline instead of AA (Mascolo et al., 1995).

The pretreated groups received diacerein or sulfasalazine orally daily for 7 days before induction of colitis and for another 3 days following colitis-induction. Blood samples were collected from the tail vein. Serum was separated by centrifugation and stored at -80 $^{\circ}$ C until used for measuring serum IL-1 β and TNF- α . Then, rats were sacrificed. After dissection, the colonic specimens were kept in 10% formalin for histopathological examination. The remaining colonic tissues were maintained at -80 $^{\circ}$ C till homogenized and used for assessment of MDA, SOD activities and caspase 3 gene expression.

Biochemical studies

Sera stored at -80 $^{\circ}$ C was used to determine TNF- α and IL-1 β levels. Homogenized tissue samples were used for the measurement of MDA, SOD activities and caspase 3 gene expression.

Measurement of tissue MDA

Colonic content of malondialdehyde (MDA) was measured according to the thiobarbituric acid method, previously described by Buege and Aust (1978). It depends on measuring MDA, the breakdown products of lipid peroxides.

Measurement of tissue SOD activity

The enzymatic activity of SOD was estimated according to the manufacturers' guidelines using commercially available kits.

Measurement of serum levels of TNF- α and IL-1 β

Serum levels of IL-1 β and TNF- α were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.

Gene expression of caspase 3

According to the manufacturer instructions, isolation of RNA from 100 mg of tissue was done by the aid of an RNA extraction kit (Qiagene, USA). After synthesis of first-strand complementary DNA from 2 μ g total RNA (Invitrogen Inc., Carlsbad, California, USA) and denaturing the template RNA and primers (25 pmol of each reverse oligonucleotide primer) at 70°C for 10 min, 40 U reverse transcriptase was added in the presence of RT buffer, 4 μ l dNTP mix (250 μ mol/l each), 40 U RNase inhibitor, and RNase-free water to achieve the final volume. Incubation of the mixture (50 μ l) was done for 1 h at 43°C, then stopped at 4°C, and used on the spot for polymerase chain reaction (PCR) or kept at -80°C until use. Reactions were carried out in triplicate. Conditions of the reaction were: an initial 15 min at 95°C, followed by 40 cycles of 15 s at 94°C, 30 s at 55 to 60°C, and 30 s at 72°C. Real-time PCR was carried out in an ABI Prism 7500 Sequence Detection System (Applied Biosystems, Foster City, California, USA). Calculation of relative gene expression was done using the comparative threshold cycle (Ct) method (Livak and Schmittgen, 2001).

Assessment of colitis**Macroscopic colonic damage scoring**

According to the scoring system of Millar (Millar et al., 1996), mucosal damage was assessed using the microscope.

Inflammation scores were assigned using a scale ranging from 0 to 4: 0 indicates no macroscopic changes, 1 indicates mucosal erythema only, 2 indicates mild mucosal edema, slight bleeding, or small erosions, 3 indicates moderate edema, bleeding ulcers or erosions, and 4 indicates severe ulceration, erosions, edema and tissue necrosis.

Histological and immunohistochemical examination

Cross sections of colonic tissues were fixed in 10% formaldehyde, embedded in paraffin blocks, and cut into fine sections. Samples were collected on glass slides, stained with hematoxylin and eosin (H&E) and examined under the microscope by a pathologist in a blinded manner. An Olympus (U.TV0.5XC-3) light microscopy was used. Slides were photographed using an Olympus digital camera.

Histopathological slides were examined for destruction of the epithelium and glands, dilatation of glandular crypts, depletion and loss of goblet cells, inflammatory cells infiltration, edema, hemorrhagic mucosa and crypt abscesses (Bancroft and Garble, 2007). Immunohistochemical detection of COX2 was performed using COX2 monoclonal mouse antibody (Lab Vision Laboratories, Ferment, USA) according to the manufacturer's protocol. The slides were then counterstained, dehydrated, and mounted (C^{ote} et al., 1993).

Statistical analysis

Data were represented as means \pm standard error of the mean (SEM). Graph pad Prism 5 software was used to perform the statistical analysis and we used one-way ANOVA to do the significant difference between different groups, followed by Tukey-Kramer post hoc test for multiple comparisons with a value of $P \leq 0.05$ considered statistically significant.

Results***Effect of diacerein and sulfasalazine on oxidative stress parameters***

There was significant increase of colonic MDA with significant decrease in colonic SOD in AA-ulcerated group when compared to normal control group. Meanwhile, diacerein and sulfasalazine pretreated

groups significantly improved these parameters.

Effect of diacerein and sulfasalazine on inflammatory parameters

Acetic acid ulcerated group significantly increased serum TNF α and IL-1B. Diacerein and sulfasalazine pretreated groups significantly decreased serum TNF α and IL-1B.

Effect of diacerein and sulfasalazine on apoptosis

Caspase 3 gene expression was upregulated by AA-ulcerated group. Meanwhile, diacerein and sulfasalazine pretreated groups significantly reduced caspase 3 gene expression.

Macroscopic examination

Acetic acid caused severe edematous inflammation in the colon, with a high macroscopic scoring of colonic damage as compared to the control group. Sulfasalazine (100 mg/kg/day) significantly reduced the severity of gross lesion scores as compared to the AA group. There was an improvement in colonic damage score by diacerein (50mg/kg/day).

Histopathological and immunohistochemical changes

Normal control group showed normal colon with preserved mucin secreting glands. Meanwhile AA-ulcerated group showed mucosal ulceration and transmural inflammation. Diacerein pretreated rats appeared near normal mucosa, with ulcer healing and preserved mucin secreting glands. In sulfasalazine pretreated group, the colon is near normal structure with mild inflammation infiltrating the mucosa.

Normal control group showed negative COX2 in normal colon (with weak focal staining that didn't reach the positive cut-off). AA-ulcerated group showed strong positive COX2 (Diffuse dark staining of the mucosal inflammatory cells and the few scattered preserved colonic glands). Meanwhile, diacerein appeared near normal mucosa, with mild COX2 staining (weak staining in almost all cells). Sulfasalazine pretreated group showed normal mucosal glands with mild COX2 staining in addition to the positively stained inflammatory cells in the stroma (weak staining in almost all cells).

Table 1: Effect of diacerein and sulfasalazine on oxidative stress parameters (colonic MDA and SOD) in rats

Groups	Colonic MDA (nmol/g tissue)	Colonic SOD (U/g tissue)
Normal control group	33.54 \pm 2.34	152.72 \pm 4.12
AA-group	94.12 \pm 3.70 ^a	68.53 \pm 3.31 ^a
Dia+AA-group	42.91 \pm 2.71 ^b	136.52 \pm 3.08 ^b
Sulfa+AA-group	39.04 \pm 1.99 ^b	144.68 \pm 2.89 ^b

Results represent the mean \pm SE (n = 6), ^a Significant (p < 0.05) difference from normal control group, ^b significant (p < 0.05) difference from AA-group.[AA= acetic acid; Dia=diacerein; Sulfa=sulfasalazine; MDA= malondialdehyde; SOD= superoxide dismutase].

Table 2: Effect of diacerein and sulfasalazine on inflammatory parameters (serum TNF α and IL-1B) in rats

Groups	Serum TNF α (pg/ml)	Serum IL-1B (pg/ml)
Normal control group	10.22 \pm 1.05	99.34 \pm 3.45
AA-group	24.08 \pm 2.26 ^a	132.27 \pm 2.44 ^a
Dia+AA-group	14.45 \pm 1.24 ^b	107.81 \pm 3.15 ^b
Sulfa+AA-group	12.70 \pm 1.09 ^b	102.63 \pm 4.26 ^b

Results represent the mean \pm SE (n = 6), ^a Significant (p < 0.05) difference from normal control group, ^b significant (p < 0.05) difference from AA-group.[AA= acetic acid; Dia=diacerein; Sulfa=sulfasalazine; TNF = tumor necrosis factor; IL=interlukin].

Table 3: Effect of diacerein and sulfasalazine on apoptosis (Caspase 3) in rats

Groups	Caspase 3 gene expression
Normal control group	1.50 ± 0.12
AA-group	6.03 ± 0.56 ^a
Dia+AA-group	1.80 ± 0.14 ^b
Sulfa+AA-group	1.60 ± 0.09 ^b

Results represent the mean ± SE (n = 6), ^a Significant (p < 0.05) difference from normal control group, ^b significant (p < 0.05) difference from AA-group. [AA= acetic acid; Dia=diacerein; Sulfa=sulfasalazine].

Table 4: Effect of diacerein and sulfasalazine on macroscopic scoring of colonic tissue in rats.

Groups	Macroscoping scoring
Normal control group	00 ± 00
AA-group	3.5 ± 0.4 ^a
Dia+AA-group	1.3 ± 0.5 ^b
Sulfa+AA-group	1.00 ± 0.3 ^b

Results represent the mean ± SE (n = 6), ^a Significant (p < 0.05) difference from normal control group, ^b significant (p < 0.05) difference from AA-group.




Figure 1. Histopathological sections of colons stained by H&E representing different studied groups. A, Group I: showing normal colon with preserved mucin secreting glands (200x). B, Group II: it shows mucosal ulceration and transmurial inflammation (200x). C, Group III: showing near normal mucosa, with ulcer healing and preserved mucin secreting glands (x100). D, Group IV: showing the colon which is near normal structure with mild inflammation infiltrating the mucosa (H&E 100x)




Figure 2. Immunohistochemical stained sections of colons for COX2 antibody representing different studied groups. Staining is considered positive when dark brown cytoplasmic staining is detected in more than 10% of cells. A, Group I: showing negative COX2 in normal colon (with weak focal staining that didn't reach the positive cut-off) (200x). B, Group II: it shows strong positive COX2 (Diffuse dark staining of the mucosal inflammatory cells and the few scattered preserved colonic glands) (200x). C, Group III: showing near normal mucosa with mild COX2 staining (weak staining in almost all cells) (x200). D, Group IV: showing normal mucosal glands with mild COX2 staining in addition to the positively stained inflammatory cells in the stroma (weak staining in almost all cells) (x200).

Discussion

Inflammatory bowel disease is a chronic inflammatory disease with highly expressed enzymes such as COX-2 and inflammatory cytokines such as TNF- α , IL-1 β (Karakoyun et al., 2011). Tissue injuries in all inflammatory conditions like colitis caused by reactive oxygen metabolites (ROM). ROM increases the oxidative stress and leads to impairment of the antioxidant defenses which contributes to the pathogenesis of colitis (Iseri et al., 2009). Thus results in increased colonic MDA contents. (Girgin et al., 2000; Ek et al., 2007).

There is a strong relation between the systemic protection against inflammation and the status of antioxidant enzymes e.g., SOD as it is responsible for the conversion of superoxide to peroxide. This guards against lipid peroxidation in colon by eliminating free-radicals. Decreasing SOD activity in the colonic tissue leads to mucosal injury due to decreased ability of

scavenging oxidative radicals (Barazzone and White 2000; Krieglstein et al., 2001).

The current study showed that colonic MDA level were significantly increased with significantly decreased colonic SOD in the AA group and this in agreement with Cetinkaya and his co-workers in 2005; Al-Rejaie et al., 2013. Meanwhile, the administration of diacerein (50mg/kg/day) showed a significant decrease in MDA level. This is consistent with Refaie et al., (2015).

Serum TNF- α and IL-1 β levels significantly increased in the AA group. Diacerein limited the up-regulation of them which are believed to play a significant role in the pathogenesis of IBD. In accordance with the current findings, the clinical study of Pasin et al., (2012) demonstrated that diacerein decreases TNF α and IL-1 β levels in peritoneal fluid and prevents Baker's yeast-induced fever in young rats.

In the AA group, caspase 3 gene expression was upregulated as previously described by Kaushal et al., (2001). The current study results showed that diacerein- pretreated rats reduced caspase 3 gene expression. Similarly, Torina et al., (2015) in their study found that diacerein is able to reduce caspase 3 activity, as an index of apoptosis.

Also, histological and immune histochemical data also match the biochemical changes. Microscopical examination confirmed the previous results, where AA group showed ulceration of the colonic mucosa with inflammation. Rats pretreated with diacerein showed amelioration of AA-colitis. The scoring of AA group significantly increased as compared to the control group, whereas that of diacerein and sulfasalazine significantly decreased as compared to AA. COX2 immunoexpression showed strong positive in AA group. Meanwhile, rats pretreated with diacerein showed near normal mucosa with mild COX2 staining

Conclusion

Overall, the findings of the present study demonstrated that diacerein pretreatment (50mg/kg/day) exerted significant ameliorating effect against AA-induced UC model. This is most probably attributed to its anti-oxidant, anti-inflammatory and anti-apoptotic effects.

Conflict of interest

The authors declare that there is no conflict of interest.

References

1. Al-Rejaie SS, Abuohashish HM, Al-Enazi, MM, Al-Assaf AH, Parmar MY, Ahmed MM (2013). Protective effect of naringenin on acetic acid-induced ulcerative colitis in rats. *World J. Gastroenterol.* 19(34): 5633-5644.
2. Bancroft J, Garble M. (2007). *Theory and Practice of Histological Techniques*, 5th edition, Churchill Livingstone, Harcourt, 85–98: 310–314.
3. Barazzone C White CW (2000). Mechanisms of cell injury and death in hyperoxia. Role of cytokines and Bcl-2 family proteins. *Am. J. Respir. Cell Mol. Biol.* 22: 517.
4. Buege, J.A., Aust, S.D. (1978). Microsomal lipidperoxidation. *Methods Enzymol.* 52, 302–310.
5. C^ote A., Silva R., Cuello A. (1993). Current protocols for light microscopy immunocytochemistry, in: Cuello A.C. (Ed), *Immunohistochemistry II*. John Wiley & Sons, Chichester, 147–168.
6. Cetinkaya A, Bulbuloglu E, Kurutas EB, Ciralik H, Kantarceken B, Buyukbese MA. (2005). Beneficial effects of N-acetylcysteine on acetic acid induced colitis in rats. *Tohoku J. Exp. Med.* 206:131-139.
7. Domagala F, Martin G, Bogdanowicz P, Ficheux H and Pujol JP (2006): Inhibition of interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1: potential mechanism for diacerein effects in osteoarthritis. *Biorheology*, 43: 577-587.
8. Ek RO, Serter M, Ergin K, Yildiz Y, Cecen S, Kavak T (2007). The Effects of caffeic acid phenethyl ester (CAPE) on TNBS-induced colitis in ovariectomized rats. *Dig Dis. Sci.* 1007: 1609-1617.
9. Girgin F, Karaoglu O, Erkus M, Tuzun S, Ozutemiz O, Dincer C (2000). Effects of trimetazidine on oxidant/antioxidant status in trinitro benzene sulfonic acid-induced chronic colitis. *J. Toxicol. Environ. Health Part A.* 59:641-52.
10. Head KA, Jurenka JS (2003). Inflammatory bowel disease, part 1: ulcerative colitis-pathophysiology, conventional and alternative treatment options. *Altern. Med. Rev.* 8:247-283.
11. Iseri, SO, Ersoy Y, Ercan F, Yuksel M, Atukeren P, Gumustas K, Alican I (2009). The effect of sildenafil, a phosphodiesterase-5inhibitor, on acetic acid-induced colonic inflammation in the rat. *J. Gastroenterol. Hepatol.* 24:1142-1148.
12. Karakoyun B, Uslu U, Ercan F, Aydin MS, Yuksel M, Ogunc AV, Alican I (2011). The effect of phosphodiesterase-5 inhibition by sildenafil citrate on inflammation and apoptosis in rat

- experimental colitis. *Life Sci.* 89:402-407
13. Kaushal GP, Kaushal V, Hong X, Shah SV (2001). Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. *Kidney Int.* 60:1726-1736
 14. Krieglstein CF, Cerwinka WH, Laroux FS, Salter JW, Russell JM, Schuermann G (2001). Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide. *J. Exp. Med.* 194: 1207e18.
 15. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2- $\Delta\Delta$ CT method. *Methods* 25:402-408.
 16. Malaguti C, Vilella CA, Vieira KP, Souza GH, Hyslop S and Zollner R L (2008). Diacerein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in nonobese diabetic (NOD) mice. *Int Immunopharmacol.* 8:782-791.
 17. Mascolo N, Izzo AA, Autore G, Maiello FM, Di Carlo G, Capasso F (1995). Acetic acid-induced colitis in normal and essential fatty acid deficient rats. *J. Pharmacol. Exp. Ther.* 272:469-475.
 18. Millar AD, Rampton DS, Chander CL, Claxson AWD, Blake DR (1996). Evaluating the antioxidant potential of new treatments for inflammatory bowel disease in a rat model of colitis. *Gut.* 39:407-415
 19. Pasin JS, Ferreira AP, Saraiva AL, Ratzlaff V, Andrighetto R, Tomazetti J, Avila DS, Alves SH, Rubin MA, Ferreira J, Santos AR and Mello CF (2012). Diacerein decreases TNF-alpha and IL-1beta levels in peritoneal fluid and prevents Baker's yeast-induced fever in young rats *Inflamm Res.* 59:189-196.
 20. Perrier S, Darakhshan F and Hajduch E (2006). IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? *FEBS Lett.* 580:6289-6294.
 21. Qiu W, Wu B, Wang X, Buchanan ME, Regueiro MD, Hartman DJ, Schoen RE, Yu J, Zhang L (2011). PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. *J. Clin. Investig.* 121(5):1722.
 22. Refaie M.M., Amin E.F., El-Tahawy N.F., Abdelrahman A.M. (2015) Possible protective effect of diacerein on doxorubicin-induced nephrotoxicity in rats. *J. Toxicol.* 2016 9507563
 23. Salari-Sharif P, Abdollahi M (2010). Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review. *Curr. Pharm. Design.* 16(33):3661-3667
 24. Sturm A, de Souza HS, Fiocchi, C (2008). Mucosal T cell proliferation and apoptosis in inflammatory bowel disease. *Current Drug Targets.* 9(5): 381-387.
 25. Thippeswamy BS, Mahendran S, Biradar MI, Raj P, Srivastava K, Badami S, Veerapur VP. (2011). Protective effect of embelin against acetic acid induced ulcerative colitis in rats. *Eur J Pharmacol.* 654:100-5.
 26. Torina AG, Reichert K, Lima F, de Souza Vilarinho KA, de Oliveira PP, do Carmo HR, de Carvalho DD, Saad MJ, Sposito AC, Petrucci O. (2015). Diacerein improves left ventricular remodeling and cardiac function by reducing the inflammatory response after myocardial infarction. *PLoS One.* 27; 10(3):e0121842.
 27. Verbruggen G (2006): Chondroprotective drugs in degenerative joint diseases. *Rheumatology (Oxford)*, 45:129-138.
 28. Wan P, Chen H, Guo Y, Bai AP (2014). Advances in treatment of ulcerative colitis with herbs: from bench to bedside. *World J. Gastroenterol.* 20(39):14099